



Recent Updates in Drugs Used in Management of Portal Hypertension

Nivedha M¹, Lakshmi T^{*2}, Don K R³

¹Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, Tamil Nadu, India

²Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, Tamil Nadu, India

³Department of Oral and Maxillofacial Pathology, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai, Tamil Nadu, India

Article History:

Received on: 08 Sep 2020

Revised on: 08 Oct 2020

Accepted on: 14 Oct 2020

Keywords:

Portal Hypertension,
Esophageal Varices,
Gastric Varices,
Ascites,
Hepatic Encephalopathy

ABSTRACT

Portal hypertension is an expansion in the weight inside the gateway vein i.e., the vein that conveys blood from the stomach related organs to the liver. The expansion in pressure is brought about by a blockage in the blood course through the liver. The advancement of gateway hypertension in a patient with cirrhosis can cause genuine clinical results which can be lethal if untreated and dynamic. Along these lines it is essential to analyze portal hypertension to postpone the movement and to treat the serious difficulties of gateway hypertension. This survey centers around the ongoing updates in drugs utilized in the administration of portal hypertension.



*Corresponding Author

Name: Lakshmi T

Phone:

Email: lakshmi@saveetha.com

ISSN: 0975-7538

DOI: <https://doi.org/10.26452/ijrps.v11iSPL3.3469>

Production and Hosted by

IJRPS | <https://ijrps.com>

© 2020 | All rights reserved.

INTRODUCTION

A medication is a synthetic substance creating a natural impact or change. Gateway hypertension is an expansion in the weight inside the portal vein i.e., the vein that conveys blood from the stomach related organs to the liver (Anitha and Ashwini, 2017). Or at the end of the day, the portal hypertension is an every now and again experienced clinical disorder caused because of a neurotic increment in the venous weight inside the portal framework. This expansion in the weight is brought about by a block-

age in the blood moving through the liver (Ezhilarasan, 2018). Hemodynamically, gateway hypertension is characterized by an expansion in the venous weight slope over the liver, which is determined from its inflow through the portal vein versus its surge through the hepatic veins. The outcome can be 1-5 mm Hg, which is ordinary. Portal hypertension prompts expanded intrahepatic obstruction, causing fibrosis and regenerative knobs (Gheena and Ezhilarasan, 2019). The improvement of portal hypertension in a patient with cirrhosis can be an indication of poor visualization Because the gateway hypertension, if not rewarded, might cause genuine clinical results and it might be lethal (Ezhilarasan et al., 2018). Along these lines, it is critical to analyze entry hypertension prior and treat the inconveniences that are brought about by gateway hypertension before they emerge. This survey centers around the ongoing updates in drugs utilized in the administration of entrance hypertension.

Non-cirrhotic portal hypertension

Any clinical condition that meddles with bloodstream inside the entrance framework can cause gateway hypertension when cirrhosis is the most

widely recognized reason (Ashwini *et al.*, 2017). But entry hypertension without cirrhosis, is called Non-Cirrhotic portal hypertension. The Non-Cirrhotic entrance hypertension can be ordered into prehepatic, intrahepatic and posthepatic dependent on the site of protection from the bloodstream (Rajekar *et al.*, 2011). The prehepatic entrance hypertension is frequently brought about by entry vein apoplexy, which can be for the most part because of hypercoagulable conditions in the grown-ups (Lakshmi *et al.*, 2015). The hypercoagulable conditions are myeloproliferative clutters, for example, polycythemia, thrombocytosis and so on (Bosch *et al.*, 2009).

The intrahepatic entry hypertension can be partitioned into presinusoidal gateway hypertension, sinusoidal portal hypertension and postsinusoidal portal hypertension as indicated by the consequences of hepatic vein catheterization (Sharma *et al.*, 2019). Presinusoidal hypertension is seen in idiopathic entrance hypertension, while sinusoidal hypertension is seen in most incessant liver infections and the postsinusoidal hypertension is seen in sinusoidal deterrent condition (Berzigotti *et al.*, 2013). The differential finding is by Non-particular beta blockers and endoscopic variceal ligation, transjugular intrahepatic portosystemic shunt, anticoagulation and in the most exceedingly awful and extreme cases it is Liver transplantation (Schouten *et al.*, 2011).

Clinically significant portal hypertension

Clinically critical gateway hypertension is characterized by a hepatic venous weight slope (≥ 10 mm Hg) in the cirrhotic patients, which might be identified with the improvement of Ascites and Varices. As of now, the ongoing procedures to quantify the hepatic venous weight angle are obtrusive and expensive (Roccarina *et al.*, 2019). Additionally expressed as gateway hypertension from incessant liver infection can be characterized by a hepatic venous weight angle above 5mm Hg (Garcia-Tsao *et al.*, 2017). On the off chance that the weight slope is over the basic limit of 10mm Hg, the patients with clinically noteworthy entry hypertension has greater chance of getting influenced by hepatic encephalopathy, post careful decompensation, hepatocellular carcinoma and so on., (Ripoll *et al.*, 2007). The clinically noteworthy entrance hypertension can expand the danger of 3 and multi year death rate (Ezhilarasan *et al.*, 2017a). Conversely in the longitudinal examinations, if the hepatic venous weight inclination tumbles to under 12mm Hg, which is diminished by in any event 20% from the standard qualities, it can forestall variceal seeping with the assistance of med-

ication therapy (Berzigotti, 2017). The treatment comprises volume revival, vasoactive medications to diminish entrance pressures i.e., octreotide, critical endoscopy inside 12 hours (Perumalsamy *et al.*, 2018).

Non-invasive assessment of clinically significant portal hypertension

The physical tests for the clinically noteworthy entrance hypertension are bug nevi and noticeable stomach portosystemic securities (Mehta *et al.*, 2019). The principal line imaging method for the determination and followup of the patients with entry hypertension is ultrasonography. It is the principal inclination due to its non-intrusiveness, cost viability and capacity to effortlessly perform even on the patient's bedside (Berzigotti *et al.*, 2008). The US doppler has more than 80 of the explicitness in diagnosing clinically huge entry hypertension (Garcia-Tsao *et al.*, 2017). Spleen firmness estimation by means of transient elastography has been a potential noninvasive substitute for entry hypertension (Ma *et al.*, 2016). Attractive reverberation elastography is one of the new procedures that assesses both liver solidness and spleen firmness by beating the constraints of ultrasonography-elastography techniques (Singh *et al.*, 2016). The (NITs) Non-obtrusive tests are 4 serum biomarker, ultrasonography, ultrasound elastography, indocyanine green freedom, attractive reverberation and processed tomography (Wai, 2003).

Esophageal varices(ov) and gastric varices(gv)

Esophageal varices are extended veins in the throat. They're regular because of a discouraged blood course through the gateway vein, which conveys blood from the digestive tract, pancreas and spleen to the liver. Beforehand, the patients were prescribed to be screened by the technique for esophagogastroduodenoscopy for varices at analysis (de Franchis, 2010). The symptomatic tests that are generally utilized for the esophageal varices are platelet tally, platelet tally to spleen length, liver solidness estimation and spleen firmness estimation (Colli *et al.*, 2017). The essential prophylaxis of variceal discharge is suggested for the patients with medium or enormous varices, patients with little varices with red rib signs and furthermore with decompensated patients with little varices (Brocchi *et al.*, 1988). The treatment for this incorporates non selective beta-blockers, propranolol, nadolol, carvedilol (Gluud and Krag, 2012). The variceal discharge is a genuine health related crisis which has a multi year mortality differing from 20% to 80% contingent on different side effects present (D'Amico *et al.*, 2014).

Gastric varices are the widened submucosal veins in the stomach, which can be a dangerous reason for seeping in the upper gastrointestinal tract (Ezhilarasan *et al.*, 2017b). It is generally found in patients with portal hypertension, expanded weight in the gateway vein framework or in patients with cirrhosis (Menon *et al.*, 2018). Gastric varices happen in practically 20% of patients with cirrhosis. As indicated by Sarin's characterization, Gastric varices can be grouped into GOV1, GOV2, segregated GV type 1 (IGV1) and IGV2 (Sarin *et al.*, 1992). The proof of essential prophylaxis is seldom observed in case of gastric varices. The Cyanoacrylate infusion has fundamentally brought down the draining rate than the non-specific beta-blockers (Mishra *et al.*, 2011). The essential administration of the gastric variceal discharge is clinically like the administration of the esophageal variceal drain which incorporates volume revival, blood transfusion, vasoactive medications, anti-infection agents and an earnest endoscopy (Rajeshkumar *et al.*, 2018a). However, the meta investigation between Cyanoacrylate infusion and other treatment of gastric variceal discharge, the first has a fundamentally lower rebleeding rate (Castellanos *et al.*, 2015). The pathophysiology of varices incorporates intrahepatic hemodynamics and additional hepatic hemodynamics (Kibrit *et al.*, 2018).

Ascites

Ascites can be characterized as the obsessive collection of liquid in the peritoneal cavity (D'Amico *et al.*, 2006). It is viewed as a decompensation occasion with a one year death pace of 20% (D'Amico *et al.*, 2006). The gateway hypertension is an essential pathophysiological component where the entry pressure more than 12mm Hg is required for the maintenance of fluid. Portal hypertension related ascites are precisely analyzed by ascitic liquid investigation and computation of the serum ascites egg whites gradient [≥ 1.1 g/dL] in 97% of the cases (Karthiga *et al.*, 2018).

The primary driver of treatment in patients with ascites is because of dietary sodium limitation and oral diuretics like oral spironolactone etc., (Runyon, 2009). Diminishing the reasons for things that irritate the etiology of the liver like liquor utilization can drastically improve in ascites than the outcomes given by clinical treatment or goals of ascites (Rajeshkumar *et al.*, 2018b). The treatment alternative for ascites can incorporate sequential restorative paracentesis, TIPS and liver transplantation in serious cases (Runyon, 1994).

Hepatic encephalopathy

Hepatic encephalopathy is characterized as the loss

of cerebrum work when a harmed liver doesn't expel poisons from the blood (Sharma *et al.*, 2013). It for the most part happens in patients with constant liver ailment like cirrhosis, hepatitis, and so on., This may cause dehydration, confusion, infections, fatigue, terrible breath from liver sickness, touchiness. The early indications incorporate distraction, confusion, breath with sweet or smelly odour (Riggio *et al.*, 2012). Propelled side effects are shaking of arms, disorientation and slurred discourse. The hepatic encephalopathy which is otherwise called portosystemic encephalopathy which alludes to the range of neurocognitive appearances in patients who experienced adjusted rest cycle, diminished ability to focus, torpid state, etc. The chance is 5-25% in the initial five years after cirrhosis determination and it is relying upon the nearness of other hazard factors (Vilstrup *et al.*, 2014). The hepatic encephalopathy is connected with encouraging occasions like dehydration, the utilization of tranquilizers, blockage, renal failure, infection or now and again gastrointestinal bleeding (Strauss *et al.*, 1992). In extreme liver infection harmed hepatocytes and advancement of portosystemic shunts brings about smelling salts being ineffectively processed by liver, bypassing and gathering in the foundational disseminations and cross blood-mind hindrance and causing astrocyte swelling (Suraweera *et al.*, 2016). Lactulose, a nonabsorbable disaccharide, is the main decision of treatment for hepatic encephalopathy also for optional prophylaxis of hepatic encephalopathy (Vilstrup *et al.*, 2014). The medications like rifaximin are the best decision of treatment because of its well being, viability and tolerability (Suraweera *et al.*, 2016). Be that as it may, the mix treatment of rifaximin with lactulose can be utilized for intermittent hepatic encephalopathy. Likewise intravenous L-ornithine, L-aspartate, Neomycin, Metronidazole and zinc can likewise be used (Vilstrup *et al.*, 2014).

CONCLUSION

The seriousness of portal hypertension obviously means one expanded mortality chance. The appraisal of portal hypertension and its clinical confusions alongside different techniques like research center markers in the mix with imaging modalities. In the ongoing not many years, the innovation has altogether continued or capacity to anticipate, treat and screen the patients with clinically noteworthy entrance hypertension yet with less number of intrusive tests. As we have expanded information about the causes and treatment of cutting edge liver malady that prompts clinically critical portal hypertension and furthermore better explanation

of medicines for clinically huge gateway hypertension, we can oversee patients with cirrhosis and gateway hypertension more noteworthy. The patients with entry hypertension are overseen by gastroenterologists, hepatologists and interventional radiologists to postpone the requirement for liver transplant and securely connect the patients to liver transplantation

Conflict of interest

The authors declare that they have no conflict of interest for this study.

Funding support

The authors declare that they have no funding support for this study.

REFERENCES

- Anitha, R., Ashwini, S. 2017. Antihyperglycemic activity of *Caralluma fimbriata*: An In vitro approach. *Pharmacognosy Magazine*, 13(51):499.
- Ashwini, S., Ezhilarasan, D., Anitha, R. 2017. Cytotoxic Effect of *Caralluma fimbriata* Against Human Colon Cancer Cells. *Pharmacognosy Journal*, 9(2):204–207.
- Berzigotti, A. 2017. Non-invasive evaluation of portal hypertension using ultrasound elastography. *Journal of Hepatology*, 67(2):399–411.
- Berzigotti, A., Gilabert, R., Abraldes, J. G., Nicolau, C., Bru, C., Bosch, J., García-Pagan, J. C. 2008. Non-invasive Prediction of Clinically Significant Portal Hypertension and Esophageal Varices in Patients With Compensated Liver Cirrhosis. *The American Journal of Gastroenterology*, 103(5):1159–1167.
- Berzigotti, A., Seijo, S., Reverter, E., Bosch, J. 2013. Assessing portal hypertension in liver diseases. *Expert Review of Gastroenterology and Hepatology*, 7(2):141–155.
- Bosch, J., Abraldes, J. G., Berzigotti, A., García-Pagan, J. C. 2009. The clinical use of HVPG measurements in chronic liver disease. *Nature Reviews Gastroenterology and Hepatology*, 6(10):573–582.
- Brocchi, E., et al. 1988. The Study and Treatment of Esophageal, and The North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the First Variceal Hemorrhage in Patients with Cirrhosis of the Liver and Esophageal Varices. *New England Journal of Medicine*, 319(15):983–989.
- Castellanos, E. R., Seron, P., Gisbert, J. P., Cosp, X. B. 2015. Endoscopic injection of cyanoacrylate glue versus other endoscopic procedures for acute bleeding gastric varices in people with portal hypertension. *Cochrane Database of Systematic Reviews*, 5.
- Colli, A., Gana, J. C., Yap, J. 2017. ... Count, Spleen Length, and Platelet Count-to-spleen Length Ratio for the Diagnosis of Oesophageal Varices in People with Chronic Liver Disease or Portal Vein Thrombosis. *Cochrane Database of Systematic Reviews*.
- D'Amico, G., Garcia-Tsao, G., Pagliaro, L. 2006. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. *Journal of Hepatology*, 44(1):217–231.
- D'Amico, G., Pasta, L., Morabito, A., D'Amico, M., Caltagirone, M., Malizia, G., Tinè, F., Giannuoli, G., Traina, M., Vizzini, G., Politi, F., Luca, A., Virdone, R., Licata, A., Pagliaro, L. 2014. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. *Alimentary Pharmacology and Therapeutics*, 39(10):1180–1193.
- de Franchis, R. 2010. Revising consensus in portal hypertension: Report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. *Journal of Hepatology*, 53(4):762–768.
- Ezhilarasan, D. 2018. Oxidative stress is bane in chronic liver diseases: Clinical and experimental perspective. *Arab Journal of Gastroenterology*, 19(2):56–64.
- Ezhilarasan, D., Lakshmi, T., Nagaich, U., Vijayaragavan, R. 2017a. Acacia catechu ethanolic seed extract triggers apoptosis of SCC-25 cells. *Pharmacognosy Magazine*, 13(51):405–405.
- Ezhilarasan, D., Lakshmi, T., Vijayaragavan, R., Bhullar, S., Rajendran, R. 2017b. Acacia catechu ethanolic bark extract induces apoptosis in human oral squamous carcinoma cells. *Journal of Advanced Pharmaceutical Technology and Research*, 8(4):143.
- Ezhilarasan, D., Sokal, E., Najimi, M. 2018. Hepatic fibrosis: It is time to go with hepatic stellate cell-specific therapeutic targets. *Hepatobiliary and Pancreatic Diseases International*, 17(3):192–197.
- Garcia-Tsao, G., Abraldes, J. G., Berzigotti, A., Bosch, J. 2017. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. *Hepatology*, 65(1):310–335.
- Gheena, S., Ezhilarasan, D. 2019. Syringic acid triggers reactive oxygen species-mediated cytotoxicity in HepG2 cells. *Human & Experimental Toxicology*, 38(6):694–702.
- Gluud, L. L., Krag, A. 2012. Banding ligation versus beta-blockers for primary prevention in oesophageal varices in adults. *Cochrane Database*

- of *Systematic Reviews*, 8.
- Karthiga, P., Rajeshkumar, S., Annadurai, G. 2018. Mechanism of Larvicidal Activity of Antimicrobial Silver Nanoparticles Synthesized Using *Garcinia mangostana* Bark Extract. *Journal of Cluster Science*, 29(6):1233-1241.
- Kibrit, J., Khan, R., Jung, B. H., Koppe, S. 2018. Update on Portal Hypertension: Clinical Assessment and Management of Portal Hypertension. *Seminars in interventional radiology*, 35:153-59.
- Lakshmi, T., Krishnan, V., Rajendran, R., Madhusudhanan, N. 2015. *Azadirachta indica* : A herbal panacea in dentistry - An update. *Pharmacognosy Reviews*, 9(17):41.
- Ma, X., Wang, L., Wu, H., Feng, Y., Han, X., Bu, H., Zhu, Q. 2016. Spleen Stiffness Is Superior to Liver Stiffness for Predicting Esophageal Varices in Chronic Liver Disease: A Meta-Analysis. *PLOS ONE*, 11(11).
- Mehta, M., Deeksha, Tewari, D., Gupta, G., Awasthi, R., Singh, H., Pandey, P., Chellappan, D. K., Wadhwa, R., Collet, T., Hansbro, P. M., Kumar, S. R., Thangavelu, L., Negi, P., Dua, K., Satija, S. 2019. Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases. *Chemico-Biological Interactions*, 308:206-215.
- Menon, S., Devi, K. S. S., Santhiya, R., Rajeshkumar, S., Kumar, S. V. 2018. Selenium nanoparticles: A potent chemotherapeutic agent and an elucidation of its mechanism. *Colloids and Surfaces B: Biointerfaces*, 170:280-292.
- Mishra, S. R., Sharma, B. C., Kumar, A., Sarin, S. K. 2011. Primary prophylaxis of gastric variceal bleeding comparing cyanoacrylate injection and beta-blockers: A randomized controlled trial. *Journal of Hepatology*, 54(6):1161-1167.
- Perumalsamy, H., Sankarapandian, K., Veerappan, K., Natarajan, S., Kandaswamy, N., Thangavelu, L., Balusamy, S. R. 2018. In silico and in vitro analysis of coumarin derivative induced anticancer effects by undergoing intrinsic pathway mediated apoptosis in human stomach cancer. *Phytomedicine*, 46:119-130.
- Rajekar, H., Vasishtha, R. K., Chawla, Y. K., Dhiman, R. K. 2011. Noncirrhotic Portal Hypertension. *Journal of Clinical and Experimental Hepatology*, 1(2):94-108.
- Rajeshkumar, S., Agarwal, H., Kumar, S. V., Lakshmi, T. 2018a. Brassica oleracea Mediated Synthesis of Zinc Oxide Nanoparticles and its Antibacterial Activity against Pathogenic Bacteria. *Asian Journal of Chemistry*, 30(12):2711-2715.
- Rajeshkumar, S., Kumar, S. V., Ramaiah, A., Agarwal, H., Lakshmi, T., Roopan, S. M. 2018b. Biosynthesis of zinc oxide nanoparticles using *Mangifera indica* leaves and evaluation of their antioxidant and cytotoxic properties in lung cancer (A549) cells. *Enzyme and Microbial Technology*, 117:91-95.
- Riggio, O., Nardelli, S., Moscucci, F., Pasquale, C., Ridola, L., Merli, M. 2012. Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt. *Clinics in Liver Disease*, 16(1):133-146.
- Ripoll, C., Groszmann, R., Garcia-Tsao, G., Grace, N., Burroughs, A., Planas, R., Escorsell, A., Garcia-Pagan, J. C., Makuch, R., Patch, D., Matloff, D. S., Bosch, J. 2007. Hepatic Venous Pressure Gradient Predicts Clinical Decompensation in Patients With Compensated Cirrhosis. *Gastroenterology*, 133(2):481-488.
- Roccarina, D., Saffioti, F., Rosselli, M., Mantovani, A., Stupia, R., Marshall, A., Thorburn, D. 2019. OTU-12 Spleen stiffness has a good performance in predicting clinically significant portal hypertension in PSC. *Gut*, 68(2):107-115.
- Runyon, B. A. 1994. Care of Patients with Ascites. *New England Journal of Medicine*, 330(5):337-342.
- Runyon, B. A. 2009. Management of adult patients with ascites due to cirrhosis: An update. *Hepatology*.
- Sarin, S. K., Lahoti, D., Saxena, S. P., Murthy, N. S., Makwana, U. K. 1992. Prevalence, classification and natural history of gastric varices: A long-term follow-up study in 568 portal hypertension patients. *Hepatology*, 16(6):1343-1349.
- Schouten, J. N., Garcia-Pagan, J. C., Valla, D. C., Janssen, H. L. 2011. Idiopathic noncirrhotic portal hypertension. *Hepatology*, 54(3):1071-1081.
- Sharma, B. C., Sharma, P., Lunia, M. K., Srivastava, S., Goyal, R., Sarin, S. K. 2013. A Randomized, Double-Blind, Controlled Trial Comparing Rifaximin Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy. *American Journal of Gastroenterology*, 108(9):1458-1463.
- Sharma, P., Mehta, M., Dhanjal, D. S., Kaur, S., Gupta, G., Singh, H., Thangavelu, L., Rajeshkumar, S., Tambuwala, M., Bakshi, H. A., Chellappan, D. K., Dua, K., Satija, S. 2019. Emerging trends in the novel drug delivery approaches for the treatment of lung cancer. *Chemico-Biological Interactions*, 309:108720.
- Singh, S., Venkatesh, S. K., Loomba, R., Wang, Z., Sirilin, C., Chen, J., Yin, M., Miller, F. H., Low, R. N., Hassanein, T., Godfrey, E. M., Asbach, P., Murad, M. H., Lomas, D. J., Talwalkar, J. A., Ehman, R. L. 2016. Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diag-

- nostic accuracy systematic review and individual participant data pooled analysis. *European Radiology*, 26(5):1431-1440.
- Strauss, E., Tramote, R., Silva, E. P. S., Caly, W. R., Honain, N. Z., Maffei, R. A., Sá, M. F. D. 1992. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. *Hepato-Gastroenterology*, 39(6):542-545.
- Suraweera, D., Sundaram, V., Saab, S. 2016. Evaluation and Management of Hepatic Encephalopathy: Current Status and Future Directions. *Gut and Liver*, 10(4):509-519.
- Vilstrup, H., Amodio, P., Bajaj, J., Cordoba, J., Ferenci, P., Mullen, K. D., Weissenborn, K., Wong, P. 2014. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver. *Hepatology*, 60(2):715-735.
- Wai, C. 2003. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology*, 38(2):518-526.